HIV and AIDS Research News & Events
Learn about upcoming meetings relevant to HIV malignancies and recent news about NCI HIV/AIDS and HIV malignancy research.
News
Researchers in the HIV and AIDS Malignancy Branch, CCR reported trial results showing that treatment of aggressive HIV-associated primary central nervous lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate is associated with high response rate, CD4+ lymphocyte reconstitution, and long-term survival with preservation or improvement of neurocognitive function.
Blood
July 2020
On May 14, 2020 FDA approves pomalidomide for AIDSrelated Kaposi sarcoma. The approval of Pomalyst was as a result of a Phase 1/2 clinical trial in patients with HIV-positive and HIV-negative symptomatic Kaposi sarcoma conducted by a team led by Dr. Robert Yarchoan of the HIV and AIDS Malignancy Branch.
Results from a large clinical trial supported by NCI and NIAID demonstrated that patients with advanced AIDS-associated Kaposi sarcoma have
improved outcomes when treated with antiretroviral therapy and the chemotherapy drug paclitaxel.
Lancet
March 2020
The NIH Record highlighted the 25th Anniversary of Kaposi sarcoma-associated herpesvirus (KSHV) which was celebrated at the 17th International Conference on Malignancies in HIV/AIDS. At the meeting Dr. Douglas Lowy, then acting director of NCI, presented the NCI Director's award to Drs. Patrick Moore and Yuan Chang for their discovery two of the known oncogenic viruses (KSHV and Merkel cell polyomavirus) and their research to elucidate the biology of these viruses.
October 2019
Read about Dr. Robert Yarchoan and the Office of HIV and AIDS Malignancy. This article highlights OHAM's efforts in HIV/AIDS malignancy research.
POZ
July 2019
Researchers from NCI and the Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab.
JAMA Oncology
June 2019
Researchers from the AIDS Malignancy Consortium have completed a cervical cancer trial in sub-Saharan Africa showing that women living with HIV can be treated with concomitant chemoradiotherapy using the same dose as HIV-negative women.
Gynecologic Oncology
April 2019
Researchers at NCI have demonstrated that cytokine dysregulation is a hallmark of primary effusion lymphoma pathogenesis, symptom profile and natural history.
Blood
February 2019
The latest information on the epidemiological, clinical features and treatment options for Kaposi sarcoma is highlighted in this review.
Nature Reviews Disease Primers
January 2019
Two independent groups describe circular RNAs in Kaposi sarcoma herpesvirus (KSHV) infected cells that may play a role in viral replication and pathogenesis.
Proceedings of the National Academy of Sciences
December 2018
Proceedings of the National Academy of Sciences
September 2018
A NCI and NIAID supported clinical trial for Kaposi sarcoma (KS) suggests that paclitaxel is a superior treatment when compared to bleomycin and vincristine with ART or oral etoposide with ART for patients with advanced KS in low resource settings.
June 2018
Investigators at the Center for Cancer Research, NCI describe how different simian immunodeficiency virus (SIV) vaccines respond differently to outside stimuli. The activation of hypoxia and the inflammasome in CD14+ monocytes result in a decrease risk of SIV acquisition.
Nature Medicine
May 2018
Investigators at NCI identify the receptor for one of the HLA proteins (HLA-E) as a potential new target for HIV treatment. Blockade of this pathway has been implicated in many cancers and autoimmune diseases. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells Science January 2018 People living with HIV have an increased cancer burden, even in the absence of over immunosuprresion. In this review, NCI researchers Drs. Yarchoan and Uldrick describe the current epidemiology, pathogenesis and prevention strategies of HIV-associated cancers and related diseases. HIV-Associated Cancers and Related Diseases New England Journal of Medicine March 2018
NCI supported researchers have determined the structure of the Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8. This may provide a target for the development of antiviral agents. Structure and mutagenesis reveal essential capsid protein interactions for KSHV replication Nature January 2018 Recommendations for eligibility for HIV-positive patients to enroll in oncology clinical trials Journal of Clinical Oncology October 2017
Structural map of Kaposi sarcoma-associated herpesvirus RNA provides clues to molecular interactions
News - Center for Cancer Research
April 2017
Possible new treatment for Kaposi sarcoma
News - Center for Cancer Research
December 2016
Ultraviolet Radiation and Kaposi Sarcoma Incidence in a Nationwide US Cohort of HIV-Infected Men
Journal of the National Cancer Institute
October 2016
Events
Registration for the annual meeting of the Collaborative U54 Consortia in HIV-Associated Cancers is now open. March 30-April 1, 2020 Gaborone, Botswana The registration deadline is March 23, 2020
23rd International Conference on Kaposi’s Sarcoma Herpesvirus (KSHV) and Related Agents June 22-25, 2020 Hotel White Sands Resort & Conference Centre Dar es Salaam, Tanzania